Short Interest in Telesis Bio, Inc. (NASDAQ:TBIO) Drops By 51.4%

Telesis Bio, Inc. (NASDAQ:TBIO) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 12,300 shares, a drop of 51.4% from the August 15th total of 25,300 shares. Based on an average daily volume of 127,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.7% of the company’s stock are short sold.

Telesis Bio Stock Down 11.6 %

Shares of TBIO stock traded down $0.21 during trading on Friday, hitting $1.60. 239,985 shares of the company were exchanged, compared to its average volume of 72,849. The company has a debt-to-equity ratio of 22.76, a quick ratio of 1.72 and a current ratio of 1.89. The firm has a market capitalization of $2.69 million, a price-to-earnings ratio of -0.06 and a beta of 1.73. The business’s 50-day simple moving average is $3.68 and its 200 day simple moving average is $5.25. Telesis Bio has a twelve month low of $1.45 and a twelve month high of $24.48.

Telesis Bio (NASDAQ:TBIO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($7.03) EPS for the quarter. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $6.50 million. Telesis Bio had a negative return on equity of 359.32% and a negative net margin of 282.58%.

About Telesis Bio

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.